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Bortezomib-melphalan-prednisone (VMP) and continuous lenalido-mide-dexamethasone (Rd) represent the standard treatment oftransplant-ineligible patients with newly diagnosed multiple
myeloma (MM). To date, no randomized trial has compared VMP to Rd,
and there is no evidence of the optimal treatment for newly diagnosed
MM, particularly in patients with high-risk cytogenetics [del(17p), t(4;14)
or t(14;16)]. We pooled together data from patients with newly diag-
nosed MM treated with VMP or Rd induction followed by lenalidomide
maintenance 10 mg (Rd-R) enrolled in the GIMEMA-MM-03-05 and
EMN01 trials, to evaluate the efficacy of these treatments in different
subgroups of patients, focusing on those with standard- and high-risk
cytogenetics. Overall, 474 patients were analyzed (VMP: 257 patients;
Rd-R: 217 patients). No differences in progression-free survival (hazard
ratio=0.96) and overall survival (hazard ratio=1.08) were observed
between standard-risk patients treated with VMP or Rd-R, whereas
among the high-risk patients, the probabilities of progression (hazard
ratio=0.54) and death (hazard ratio=0.73) were lower in the patients
treated with VMP than in those treated with Rd-R. In particular, stan-
dard-risk patients >75 years benefited less from VMP than from Rd-R
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First-line therapy in elderly MM patients
haematologica | 2020; 105(4) 1075
Introduction
Multiple myeloma (MM) is a disease that occurs pre-
dominantly in the elderly: the median age at diagnosis is
71 years and two-thirds of patients are over 65 years of
age.1,2 Elderly patients, defined as those older than 65-70
years of age, are usually considered ineligible for high-
dose chemotherapy and autologous stem-cell transplanta-
tion (ASCT).3 In Europe, standard initial therapy of older
patients consists of either a triplet regimen including
bortezomib-melphalan-prednisone (VMP) administered in
a fixed-duration schedule, or a doublet combination of
lenalidomide (25 mg) and dexamethasone (Rd), adminis-
tered continuously until progression or intolerance.3 The
VISTA trial demonstrated that VMP was superior to mel-
phalan-prednisone both in terms of progression-free sur-
vival [PFS: 21.7 vs. 15.2 months, hazard ratio (HR)=0.56;
P<0.001] and overall survival (OS: 56.4 vs. 43.1 months,
HR=0.69; P<0.001).4,5 The FIRST trial showed that contin-
uous Rd significantly prolonged the median PFS (26 vs.
21.9 months, HR=0.69; P<0.001) and OS (59.1 vs. 49.1
months, HR=0.78; P=0.0023) compared to the median PFS
and OS achieved with melphalan-prednisone-thalidomide
(MPT).6,7 Based on the results of these two phase III stud-
ies, both VMP and continuous Rd were approved by the
European Medicine Agency as standard treatments for
patients with newly diagnosed MM ineligible for ASCT. 
The most important prognostic factors in MM are age
and frailty, disease stage defined by the International
Staging System (ISS),8 and chromosomal abnormalities,
detected by fluorescent in situ hybridization (FISH).
Patients harboring chromosomal abnormalities, including
del(17p), t(4,14) and t(14,16), have a poor prognosis, with
a higher risk of disease progression and death.9
Approximately 15-20% of patients with newly diagnosed
MM present with at least one cytogenetic abnormality
and constitute the so-called “high-risk” population.
Despite recent therapeutic advances in MM, the results
obtained with novel agent-based regimens in patients
with high-risk chromosomal abnormalities are unsatisfac-
tory and the prognosis of these patients remains poor.
Moreover, limited data are available on high-risk, trans-
plant-ineligible MM patients treated with bortezomib or
lenalidomide in first-line therapy. In the VISTA trial,
patients with high- or standard-risk cytogenetics who
received VMP had similar times to progression (median
19.8 vs. 23.1 months, HR=1.29; P=0.55) and OS (HR=1.00;
P=0.99).4,5 In a subanalysis of the FIRST trial, which com-
pared continuous Rd treatment until progression, Rd treat-
ment for 72 weeks (Rd18) and MPT treatment, continuous
Rd treatment resulted in PFS and OS benefits in compari-
son with MPT; however, these benefits were largely due
to the improvements in PFS and OS in patients without
high-risk cytogenetics (median PFS 31.1 vs. 21.2 vs. 24.9
months for continuous Rd vs. Rd18 vs. MPT). Indeed, in
the high-risk group, the longest PFS was observed with
Rd18 treatment (median 8.4 vs. 17.5 vs. 14.6 months for
continuous Rd vs. Rd18 vs. MPT) while OS was similar
across treatment arms.10
Unfortunately, VMP and Rd have never been formally
compared in a randomized trial. Based on the different
safety profiles of bortezomib and lenalidomide, borte-
zomib is usually preferred in patients with advanced renal
failure, while lenalidomide can be the drug of choice for
patients with pre-existing neuropathy, or when oral ther-
apy is preferable.11 Besides these considerations, VMP and
Rd are equally recommended. Because a head-to-head
comparison of VMP vs. Rd is lacking, the choice of first-
line treatment of elderly MM patients is based mainly on
the physician’s and patient’s preferences. 
We previously published the results of two randomized,
phase III studies investigating both VMP (GIMEMA-MM-
03-05)12–14 and Rd induction followed by lenalidomide
maintenance (Rd-R) (EMN01)15 as upfront therapies for
elderly, transplant-ineligible MM patients. In order to pro-
vide clinicians with useful, and currently lacking, evidence
that may help to tailor anti-myeloma treatment better in
this population, we conducted a pooled, retrospective
analysis comparing the efficacy of VMP and Rd-R in dif-
ferent subgroups of elderly, transplant-ineligible MM
patients, focusing on cytogenetic profile.
Methods 
Study design and participants
We pooled the single data from two phase III studies, the
GIMEMA-MM-03-05 (NCT01063179) and the EMN01
(NCT01093196) trials. Both trials enrolled patients with newly
diagnosed MM who were older than 65 years of age or younger
but ineligible for ASCT. Inclusion and exclusion criteria, as well as
treatment details of the source studies, have been published previ-
ously.12–15 Further details on study treatments and procedures are
reported in the Online Supplementary Appendix. For this retrospec-
tive, not pre-planned analysis, we selected only patients random-
ized to VMP or Rd-R. The source studies were approved by the
institutional review boards at each of the participating centers. All
patients gave written informed consent before entering the source
studies, which were performed in accordance with the
Declaration of Helsinki.
Statistical analysis
The primary objective of this analysis was to compare PFS and
OS (see Online Supplementary Appendix) in patients treated with
VMP or Rd-R, adjusting for patient and disease characteristics at
baseline. 
Single data from the two studies were pooled together and ana-
lyzed. Comparisons between different groups of patients were
conducted using standard statistical tests. Time-to-event data
were analyzed using the Kaplan–Meier method; survival curves
were compared with the log-rank test. Results are presented as
hazard ratios (HR), 95% confidence intervals (95% CI), and two-
(hazard ratio for progression-free survival=0.96; hazard ratio for overall survival=1.81). In this non-ran-
domized analysis, VMP and Rd-R were equally effective in younger (≤75 years), standard-risk patients,
while older ones (>75 years) benefited more from Rd-R. In high-risk patients, VMP improved progres-
sion-free survival and overall survival irrespective of age. The source trials are registered at
ClinicalTrials.gov (NCT01063179 and NCT01093196).
sided P-values adjusted for age, ISS stage, cytogenetic risk as deter-
mined by FISH, Karnofsky Performance Status (PS) and
extramedullary disease (yes vs. no) (main model). Subgroup analy-
ses were performed to determine the consistency of treatment
effects of VMP vs. Rd-R in the main model in the different sub-
groups using interaction terms between treatment and cytogenet-
ics [also with single deletion and translocation, del(17p), t(4;14)
and t(14;16)], ISS stage (I vs. II/III), age (≤75 vs. >75 years),
Karnofsky PS (90-100 vs. 70-80 vs. 60) and extramedullary disease.
The null hypothesis examined with the interaction test was that
the HR of the comparison VMP vs. Rd-R  would be the same in
each subgroup. The models were adjusted for age as a continuous
variable. Multivariate Cox models with a three-way interaction
between treatment (VMP vs. Rd-R), cytogenetics (high-risk vs.
standard-risk, missing vs. standard-risk) and age (≤75 vs. >75 years)
were performed to evaluate the effect of treatment in different
cytogenetic and age subgroups. The models were adjusted for
other factors included in previous analyses.  The different effect of
VMP vs. Rd-R in cytogenetic subgroups was confirmed by a sen-
sitivity analysis using the multiple imputation method for missing
cytogenetic and ISS values. In detail, missing data were handled
using the “jomo” package16 to perform Cox model-compatible
multiple imputation17,18 with 50 imputations, 1,000 burn-in itera-
tions and 1,000 iterations between two successive imputations.
In both trials, FISH was assessed centrally with a 10% cutoff for
numerical aberrations and a 15% one for IgH translocations. High-
risk cytogenetics was defined as the presence of at least one of the
following chromosomal abnormalities: del(17p), t(4;14) or t(14;16).
Patients not carrying any of these abnormalities were defined as
standard-risk patients. Data were censored on June 18, 2014 for
the GIMEMA-MM-03-05 study and on October 20, 2017 for the




A total of 474 patients were analyzed, 257 in the VMP
group and 217 in the Rd-R group. Patients’ demographic
and baseline characteristics were well balanced between
the two groups (Table 1). The median age of the overall
population was 72 years [interquartile range (IQR) 69-76),
with patients in the Rd-R group being slightly older (medi-
an, 73 years; IQR 70-77) than patients in the VMP group
(median, 71 years; IQR 68-75; P<0.001). Similar propor-
tions of patients in the VMP and Rd-R groups had ISS
stage III disease (23% vs. 27%; P=0.74) and high-risk cyto-
genetics as determined by FISH (19% vs. 22%; P=1). 
All patients started the assigned treatment. Overall,
61% and 64% of patients in the VMP and Rd-R groups,
respectively, received a second-line treatment, which con-
sisted of an immunomodulatory drug (IMiD)-based regi-
men in 63% of patients treated with VMP and of a protea-
some inhibitor (PI)-based regimen in 84% of patients
treated with Rd-R (Table 2). 
The median follow-up for the entire study population
was 70.2 months (IQR 54.7-80.6), without a significant
difference between the VMP and Rd-R groups (72.6 vs.
64.4 months, respectively; P=0.16).
Survival outcomes
The median PFS in the overall population was 21.5
months (95% CI: 19.8-24.9) and was not significantly dif-
ferent between patients treated with VMP (25.1 months,
Table 2. Second-line treatment.
                                                    All patients        VMP            Rd-R        P-value
                                                      (n=474)        (n=257)       (n=217)
Second-line treatment – n (%)                                                                                   0.70
Yes                                                        296 (62)         158 (61)        138 (64)
No                                                          178 (38)           99 (39)          79 (36)
Type of treatment – n (%)
Proteasome inhibitor
bortezomib                                        144 (49)           28 (18)         116 (84)
carfilzomib                                            2 (0)                1 (0)               1 (0)
Immunomodulatory drug
lenalidomide                                      68 (23)            68 (43)            0 (0)
thalidomide                                        34 (11)            32 (20)            2 (1)
Other                                                     48 (16)            29 (18)          19 (14)
VMP: bortezomib-melphalan-prednisone; Rd-R: lenalidomide-dexamethasone followed by
lenalidomide maintenance.
Table 1. Baseline patients’ characteristics in the intention-to-treat population.
                                            All patients            VMP                 Rd-R          P-value
                                               (n=474)            (n=257)            (n=217)
Age – median (IQR)                72 (69-76)          71 (68-75)           73 (70-77)        <0.001
>75 years – n (%)                    131 (28)               57 (22)                74 (34)
Karnofsky PS – n (%)
90-100                                          232 (49)              121 (47)              111 (51)             0.11
70-80                                             200 (42)              118 (46)               82 (38)
60                                                    42 (9)                  18 (7)                 24 (11)
Creatinine – mg/dL (IQR)    1 (0.8-1.22)      1.01 (0.84-1.3)    0.94 (0.8-1.19)      0.002
LDH – UI/L (IQR)                 286 (202-377)    293 (203-368)    284 (200-381)       0.753
missing – n (%)                         80 (17)                36 (14)                44 (20)
Extramedullary                            58 (12)                37 (14)                21 (10)             0.124
disease – n (%)                                 
ISS – n (%)                                                                                                                          0.96
I                                                     117 (25)               56 (22)                61 (28)
II                                                   184 (39)               88 (34)                97 (45)
III                                                  117 (25)               57 (22)                59 (27)
Missing                                         56 (12)                56 (22)
Cytogenetics – n (%)                                                                                                          1
standard-risk                             273 (58)              136 (53)              137 (63)
high-risk*                                    95 (20)                48 (19)                47 (22)
missing                                        106 (22)               73 (28)                33 (15)                 
Del(17p) – n (%)                                                                                                                  1
no                                                  321 (68)              161 (63)              160 (74)
yes                                                 47 (10)                 23 (9)                 24 (11)
missing                                        106 (22)               73 (28)                33 (15)
t(4;14) – n (%)                                                                                                                    0.88
no                                                  318 (67)              158 (61)              160 (74)
yes                                                 50 (11)                26 (10)                24 (11)
missing                                        106 (22)               73 (28)                33 (15)
t(14;16) – n (%)                                                                                                                 0.785
no                                                  352 (74)              178 (69)              174 (80)
yes                                                  13 (3)                   6 (2)                     7 (3)
missing                                        109 (23)               73 (28)                36 (17)
t(11;14) – n (%)                                                                                                                 0.038
no                                                  308 (65)              164 (64)              144 (66)
yes                                                 54 (11)                 20 (8)                 34 (16)
missing                                        112 (24)               73 (28)                39 (18)
VMP: bortezomib-melphalan-prednisone; Rd-R: lenalidomide-dexamethasone followed by
lenalidomide maintenance; IQR: interquartile range; PS: Performance Status;  LDH: lactate dehy-
drogenase; ISS: International Staging System. *High-risk defined by the presence of any of
del(17p), t(4;14), or t(14;16), detected by fluorescence in situ hybridization. 
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95% CI: 20.9-28.6) or Rd-R (18.6 months, 95% CI: 16-
22.4) (HR=0.81, P=0.07). At 5 years, 15% and 18% of
patients were alive and free from progression in the VMP
and Rd-R groups, respectively. In the subgroup analyses
(Figure 1), no clear differences in PFS were noted between
the VMP and Rd-R groups according to age (in patients
≤75 years, HR=0.80; in patients >75 years, HR=0.84, inter-
action P=0.85), Karnofsky PS (score 90-100, HR=0.73;
score 70-80, HR= 0.86, interaction P=0.43), ISS stage (stage
I, HR=0.73; stage II/III, HR=0.85, interaction P=0.55) and
the presence of extramedullary disease (yes, HR=0.75; no,
HR=0.82, interaction P=0.78). As far as concerns FISH-
determined cytogenetic risk, no difference in PFS was
observed among standard-risk patients between the VMP
and Rd-R groups (HR=0.96, 95% CI: 0.73-1.28), whereas
in high-risk patients, a significant benefit was observed
with VMP in comparison with Rd-R (HR=0.54, 95% CI:
0.34-0.84; interaction P=0.03). The advantage of VMP
over Rd-R in high-risk patients was confirmed in the sub-
groups of single high-risk cytogenetic abnormalities,
including del(17p) (HR=0.59, 95% CI: 0.32-1.09), t(4;14)
(HR=0.50, 95% CI: 0.27-0.93) and t(14;16) (HR=0.35, 95%
CI: 0.09-1.42) (Online Supplementary Figure S1). 
The median OS in the overall population was 66.4
months (95% CI: 57.3-79.7); the median OS was not sig-
nificantly different between patients treated with VMP
(71 months; 95% CI: 58.2-not reached) or Rd-R (62
months, 95% CI: 48.2-83.3) (HR=0.85; P=0.28), with an
equivalent proportion of patients alive at 5 years (55% vs.
51%, respectively). In the subgroup analysis (Figure 2),
patients ≤75 years old benefited more from VMP than Rd-
R (HR=0.71, 95% CI: 0.51-1.00), whereas patients >75
years old benefited more from Rd-R (HR=1.29, 95% CI:
0.79-2.13; interaction P=0.04). Similarly to PFS, no signifi-
cant difference in OS was noted among standard-risk
patients between those treated with VMP or Rd-R
(HR=1.08, 95% CI: 0.74-1.58), but among patients with
high-risk cytogenetics, an OS advantage was reported for
VMP-treated patients over those treated with Rd-R
(HR=0.73, 95% CI: 0.42-1.26) and those with missing
data. The advantage for VMP over Rd-R in high-risk
patients was confirmed in the subgroups of single high-
risk cytogenetic abnormalities, including del(17p)
(HR=0.81, 95% CI: 0.38-1.71), t(4;14) (HR=0.74, 95% CI:
0.35-1.56), and t(14;16) (HR=0.73, 95% CI: 0.13-4.05)
(Online Supplementary Figure S2). 
Multivariate Cox models with three-way interaction
were performed to better evaluate the relationship
between treatment regimen (VMP vs. Rd-R), age (≤75 vs.
>75 years) and cytogenetic risk (standard vs. high). This
analysis confirmed the absence of difference in PFS
between VMP and Rd-R according to age in the standard-
risk group, while confirmed the PFS benefit from VMP
over Rd-R in high-risk patients (interaction P=0.03). With
regards to OS, older (>75 years), standard-risk patients
seemed to benefit more from Rd-R than from VMP
(HR=1.81), while the OS advantage from VMP was con-
firmed in younger (≤75 years), standard-risk patients
(HR=0.83). In high-risk patients, the OS benefit was con-
firmed irrespective of age (≤75 years, HR=0.75; >75 years,
HR=0.65) (Table 3).
To better investigate the comparison between VMP and
Rd-R and the effect of cytogenetics and age we performed
a multiple imputation analysis for missing cytogenetics
First-line therapy in elderly MM patients
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Figure 1. Subgroup analysis of progression-free survival in the intention-to-treat population for patients treated with VMP or Rd-R. VMP: bortezomib-melphalan-
prednisone; Rd-R: lenalidomide-dexamethasone followed by lenalidomide maintenance; HR: hazard ratio; 95% CI: 95% confidence interval; ISS: International Staging
System.
and ISS stage data. No difference in PFS was observed
between the groups treated with VMP or Rd-R (HR=0.85,
95% CI: 0.69-1.04); subgroup analysis confirmed the pre-
vious results for cytogenetics, with no difference for stan-
dard-risk patients (HR=1.01, 95% CI: 0.78-1.30); while, in
high-risk patients, there was a significant benefit from
VMP treatment in comparison with Rd-R treatment
(HR=0.53, 95% CI: 0.34-0.82; interaction P=0.02) (Online
Supplementary Figure S3). No difference in OS was
observed between the groups treated with VMP or Rd-R
(HR=0.86, 95% CI: 0.66-1.13); subgroup analysis revealed
that VMP was more beneficial than Rd-R for patients ≤75
years (HR=0.72, 95% CI: 0.52-0.99), whereas patients >75
years benefited more from Rd-R (HR=1.29, 95% CI: 0. 79-
2.08; interaction P=0.05) (Online Supplementary Figure S4).
Multivariate Cox models with the three-way interaction
confirmed the results for PFS and OS (Online
Supplementary Table S1).
Discussion
In this pooled analysis of 474 transplant-ineligible
patients with newly diagnosed MM, we evaluated the
impact on survival outcomes of initial treatment, consist-
ing of either a bortezomib-based regimen (VMP) or a
lenalidomide-based one (Rd-R), in different subgroups of
patients, focusing on groups with different cytogenetic risk
profiles, as determined by FISH. We found no difference
between VMP and Rd-R among standard-risk patients,
whereas, among high-risk patients, VMP improved PFS
(HR=0.54) and OS (HR=0.73) as compared to Rd-R. 
Risk assessment and stratification have long been per-
formed in MM, taking into consideration both the aggres-
siveness of the disease at presentation, based on ISS stage,
and its cytogenetic features, determined by either FISH or
gene expression profile. Many prognostic factors have
been identified in myeloma, the most important ones
being chronological and biological age, defined by frailty
status in elderly patients, and the presence of chromosomal
abnormalities identified by FISH.11
Although risk assessment had limited impact on thera-
peutic choices in the past, with the expanding armamen-
tarium of treatments for MM and the growing evidence of
effect modification, it is likely to become a fundamental
factor in selecting and tailoring treatment. The
International Myeloma Working Group (IMWG) guide-
lines recommend that all newly diagnosed (ND)MM
patients be screened by FISH for chromosomal abnormali-
ties, including del(17p), t(4;14) and t(14;16), and that all
older patients undergo a geriatric assessment for the evalu-
ation of frailty.19 Despite these recommendations, to date
no trial has prospectively evaluated the efficacy of standard
therapies according to patients’ risk status, either based on
chromosomal abnormalities identified by FISH or on
frailty status. Hence, very limited data are available about
the efficacy of current standards of care, such as VMP and
Rd, for NDMM patients with high-risk cytogenetics. The
VISTA trial did not find any difference between high-risk
and standard-risk patients treated with VMP.4,5 In the FIRST
trial, there was no evidence that lenalidomide improved
outcome of patients with high-risk cytogenetics.7
However, the small number of high-risk patients in both
trials makes it difficult to draw definitive conclusions.
In our study, we defined high-risk patients as those car-
rying at least one cytogenetic abnormality, including
A. Larocca et al.
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Figure 2. Subgroup analysis of overall survival in the intention-to-treat population for patients treated with VMP or Rd-R. VMP: bortezomib-melphalan-prednisone;
Rd-R: lenalidomide-dexamethasone followed by lenalidomide maintenance; HR: hazard ratio; 95% CI: 95% confidence interval; ISS: International Staging System.
del(17p), t(4;14) and t(14;16), consistently with the IMWG
recommendations. Major advantages of this study are the
number of patients with available cytogenetic data and the
fact that all FISH analyses were performed at one central-
ized facility only.
In our analysis, VMP resulted in a 45% reduction in the
risk of death or progression, as compared to that achieved
with Rd-R (HR=0.54), in the high-risk group, with the PFS
benefit being confirmed across the single cytogenetic
abnormalities, whereas no significant difference in PFS was
found in the standard-risk group (HR=0.96, interaction
P=0.03). Furthermore, high-risk patients treated with VMP
had a reduced risk of death (HR: 0.73), confirmed across all
cytogenetic subgroups, in comparison with patients treat-
ed with Rd-R, while no difference was noted between
patients treated with VMP or Rd-R within the standard-
risk group (HR=1.08). However, we could not distinguish
the role of melphalan from that of bortezomib in improv-
ing the outcome of high-risk patients.
The PFS benefit for VMP over Rd-R in high-risk patients
was seen in both younger (≤75 years; HR=0.75) and older
patients (>75 years; HR=0.19), while in older, standard-risk
patients VMP and Rd-R had similar effects on outcomes
(HR=0.96). Similarly, while the OS benefit among high-risk
patients was independent of age (patients ≤75 years,
HR=0.75; patients >75 years, HR=0.65), older patients
with standard-risk cytogenetics benefited less from VMP
(patients >75 years, HR=1.81) than they did from Rd-R.
No data about the patients’ frailty at diagnosis were
available in the GIMEMA-MM-03-05 trial, and chronolog-
ical age was the only parameter that could be evaluated in
the two trials included in this analysis.
In order to better assess the efficacy of approved upfront
regimens according to cytogenetic risk, we restricted our
analysis to patients randomized to the VMP arm of the
GIMEMA-MM-03-05 trial and the Rd-R arm of the
EMN01 trial, since both VMP and Rd are approved combi-
nations for patients with newly diagnosed MM who are
ineligible for transplantation. Of note, in the EMN01-trial
patients in the Rd-R arm received nine cycles of Rd fol-
lowed by lenalidomide maintenance or lenalidomide-pred-
nisone maintenance until progression (lenalidomide 10
mg/day), whereas in the standard approved regimen, Rd is
administered continuously until progression.15 This could
in part explain the inferior PFS in the EMN01 trial (21
months) as compared to that in the FIRST trial (26
months).7,15 On the other hand, we recently presented, at
an American Society of Hematology meeting, preliminary
results of a randomized phase III study comparing stan-
dard Rd to Rd-R in older, intermediate fit patients, defined
by the IMWG frailty score,19 showing no difference
between continuous Rd and Rd-R in terms of PFS
(HR=0.93, 95% CI: 0.64-1.34; P=0.681) and OS (HR=0.73,
95% CI: 0.40-1.33; P=0.306).20
In the VISTA trial, bortezomib was given twice weekly
during cycles 1 to 4 and once weekly thereafter, while in
the GIMEMA-MM-03-05-trial half of the patients in the
VMP arm (n=191, 51%) received once-weekly borte-
zomib. However, we had previously shown that the once
weekly schedule was equally effective as the twice week-
ly one in a subgroup analysis of the GIMEMA-MM-03-05
study, potentially due to a more tolerable safety profile of
once weekly bortezomib.13,14 This might explain a some-
what more favorable median PFS with VMP in the
GIMEMA-MM-03-05 study (median, 24.8 months) as
compared to the PFS  reported in the VISTA trial (median,
21.7 months).4
The major limitation of this unplanned cross-trial com-
parison is the absence of randomization between the two
treatments, so the results should be interpreted with par-
ticular caution. Despite similar eligibility criteria and a
comparable follow-up of more than 5 years, there were
some significant differences between the two populations.
In fact, patients treated with Rd-R were significantly older
and patients treated with VMP had a significantly higher
creatinine level. Another limitation is that patients enrolled
in the two source trials had to meet strict inclusion and
exclusion criteria.
Despite these caveats, a head-to-head comparison
between VMP and Rd is currently lacking, as is a prospec-
tive evaluation of the different treatments in high-risk and
standard-risk MM patients. To the best of our knowledge,
this is the first study that has pooled together and analyzed
a large series of transplant-ineligible patients with NDMM
treated with either a bortezomib- or lenalidomide-based
combination, with the aim of providing an answer to the
burning question of the optimal upfront treatment for
NDMM patients according to their cytogenetic risk.  
Our results suggest that the doublet regimen Rd may be
a suboptimal option for patients with high-risk cytogenet-
ics, further supporting the 2016 IMWG recommendations
that a triplet regimen containing an IMiD and a PI should
be used in this setting.9 In this light, a major step forward
has been made with the results of the Southwest
Oncology Group (SWOG) S0777, which showed superior
response rate, PFS and OS with the triplet regimen borte-
zomib-lenalidomide-dexamethasone (VRD) than with Rd
in NDMM without intention to immediate transplanta-
tion.21 Of note, the longest PFS in high-risk patients was
obtained with VRD (38 months). Nevertheless, the analy-
sis was based on only 44 high-risk patients.
The selection of treatment in elderly patients should also
consider the risk of toxicity and the capability to tolerate
treatment, since advanced age and the occurrence of severe
adverse events may negatively affect survival.22 In our
analysis, this was particularly evident in standard-risk
patients, in whom no difference was found between VMP
and Rd-R and the benefit of Rd-R was more evident in
patients over 75 years. In this context, the presence of spe-
cific comorbidities (such as peripheral neuropathy or renal
insufficiency), older age (>75 years) or the presence of
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Table 3. Multivariate Cox models with three-way interaction between treatment
type, age and cytogenetics, adjusted for International Staging System stage,
Karnofsky Performance Status, extramedullary disease and age as a continu-
ous variable.
Main analysis                                                  PFS                                OS
                                                                HR* (95% CI)                HR* (95% CI)
Standard-risk cytogenetics - age ≤75        0.92 (0.67 - 1.27)               0.83 (0.53 - 1.29)
Standard-risk cytogenetics - age >75        0.96 (0.56 - 1.66)               1.81 (0.94 - 3.49)
High-risk cytogenetics - age ≤75                0.75 (0.45 - 1.26)               0.75 (0.39 - 1.43)
High-risk cytogenetics - age >75                0.19 (0.07 - 0.52)               0.65 (0.21 - 2.04)
3-way interaction-P                                                    0.03                                      0.23
2-way cytogenetics interaction-P                           0.03                                      0.23
2-way age interaction-P                                             0.85                                      0.04
PFS: progression-free survival; OS: overall survival; HR: hazard ratio; 95% CI: 95% confidence
interval.
frailty, as well as the patient’s compliance and treatment
preference should be considered when choosing treatment. 
Our results highlight the importance of performing FISH
analysis in all cases of NDMM for risk stratification.
Treatment decisions in elderly patients ineligible for trans-
plant are extremely complex, since they should take into
consideration not only the biology and the stage of the dis-
ease, but also the characteristics of patients (frailty status,
comorbidities, hospitalization, concomitant medications,
social support, compliance) and goals of care (depth of
response or disease control). Therefore, both VMP and Rd
are valid options for transplant-ineligible NDMM.
Nevertheless, VMP could be preferred in patients with
high-risk cytogenetics and severe renal insufficiency,
whereas continuous Rd could be the treatment of choice in
standard-risk patients, particularly those over 75 years, or
if oral administration and avoidance of peripheral neuropa-
thy are major considerations. 
The results of this analysis are based on a selected popu-
lation, including patients enrolled in clinical trials.
Nevertheless, an ongoing trial will prospectively compare
these two standard treatments, VMP and continuous Rd,
and the impact of cytogenetics on outcomes in an unselect-
ed population of patients ≥65 years with MM in every day
clinical practice (Real MM trial, ClinicalTrials.gov
Identifier: NCT03829371).  
Better treatment options and newer combinations are
needed for high-risk disease. Recent trials incorporating the
first-in-class monoclonal antibody anti-CD38 daratumum-
ab combined with VMP (Dara-VMP)23 or Rd (Dara-Rd)24
showed that these regimes significantly reduced the risk of
progression or death by 50% and 44%, respectively, as
compared to standard VMP (Dara-VMP vs. VMP: median
PFS not reached vs. 18.1 months, HR=0.50,  95% CI: 0.38-
0.65) and Rd (Dara_Rd vs. Rd: median PFS not reached vs.
31.9 months, HR=0.56, 95% CI: 0.43-0.73). The benefit of
Dara-VMP and Dara-Rd was evident in most of the sub-
groups analyzed; however the addition of daratumumab
did not seem not to overcome the poor prognosis of high-
risk patients. 
Ongoing trials testing multi-drug combinations including
IMiD, second-generation PI, such as carfilzomib and ixa-
zomib, and monoclonal antibodies in the frontline setting
will evaluate and, potentially, improve the outcome of
high-risk patients.
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